<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        100-10-07
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2007
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NEBIDO 1000 MG- 4 ML SOLUTION FOR INJ
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TESTOSTERONE UNDECANOATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        250
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        333.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAYER AG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAYER AG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 392]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-KAMAL IMPORT OFFICE CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAYER PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03BA03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Nebido contains testosterone, a male hormone, as the active ingredient.</p><p>Nebido is injected into a muscle in your body. There it can be stored and gradually released over a period of time. Nebido is used in adult men for testosterone replacement to treat various health problems caused by a lack of testosterone (male hypogonadism). These should be confirmed by two separate blood testosterone measurements and also include clinical symptoms such as:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; impotence</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infertility</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low sex drive</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depressive moods</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone loss caused by low hormone levels</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do NOT use Nebido</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to testosterone undecanoate or any of the other ingredients of this medicine (listed in section 6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have androgen-dependent cancer or suspected cancer of the prostate or of the breast</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have or had a liver tumour</p><p>&nbsp;</p><p>Nebido <strong>is not</strong> intended for use in women.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>&nbsp;</strong></p><p><strong>Talk to your doctor</strong> before using Nebido if you have or have ever had:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; epilepsy</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart, kidney or liver problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; migraine</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; temporary interruptions in your breathing during sleep (apnoea), as these may get worse</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cancer, as the level of calcium in your blood may need to be tested regularly</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure or if you are treated for high blood pressure, as testosterone may cause a rise in blood pressure.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clotting problems</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bleeding disorders (i.e. haemophilia)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; thrombophilia (an abnormality of blood coagulation that increases the risk of thrombosis - blood clots in blood vessels)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; factors that increase your risk for blood clots in a vein: previous blood clots in a vein; smoking; obesity; cancer; immobility; if one of your immediate family has had a blood clot in the leg, lung or other organ at a young age (e.g. below the age of about 50); or as you get older.</p><p>&nbsp;</p><p>How to recognise a blood clot: painful swelling of one leg or sudden change in colour of the skin e.g. turning pale, red or blue, sudden breathlessness, sudden unexplained cough which may bring up blood; or sudden chest pain, severe light headedness or dizziness, severe pain in your stomach, sudden loss of vision. Seek urgent medical attention if you experience one of these symptoms.</p><p><strong>&nbsp;</strong></p><p><strong>If you are suffering from severe heart, liver or kidney disease</strong>, treatment with Nebido may cause severe complications in the form of water retention in your body sometimes accompanied by (congestive) heart failure.</p><p>The following blood checks should be carried out by your doctor before and during the treatment: testosterone blood level, full blood count.</p><p>&nbsp;</p><p><strong>If your liver is not working properly</strong></p><p>No formal studies have been performed in patients with liver impairment. You will not be prescribed Nebido if you have ever had a liver tumour (see<em> <strong>&ldquo;</strong>Do not use Nebido&rdquo;).</em></p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Nebido <strong>is not</strong> for use in children and adolescents. There is no data available on the use of Nebido in males under 18 years of age.</p><p><strong>&nbsp;</strong></p><p><strong>Elderly patients (65 years or older)</strong></p><p>There is no need for your doctor to adjust the dose if you are over 65 (see <em>&ldquo;Medical examination/follow up&rdquo;</em>).</p><p>&nbsp;</p><p><strong>Muscle building and drug tests</strong></p><p>Nebido is <strong>not</strong> suitable for building muscles in healthy individuals or for increasing physical strength.</p><p>Nebido might lead to positive results in drug tests.</p><p>&nbsp;</p><p><strong>Drug abuse and dependence</strong></p><p>Always take this medicine exactly as your doctor or pharmacist has told you.</p><p>Abuse of testosterone, especially if you take too much of this medicine alone or with other anabolic androgenic steroids, can cause serious health problems to your heart and blood vessels (that can lead to death), mental health and/or the liver.</p><p>Individuals who have abused testosterone may become dependent and may experience withdrawal symptoms when the dosage changes significantly or is stopped immediately. You should not abuse this medicine alone or with other anabolic androgenic steroids because it carries serious health risks. (See &quot;<em>Possible side effects</em>&quot;.)</p><p>&nbsp;</p><p><strong>Medical examination/Follow-up</strong></p><p>Male hormones may increase the growth of prostate cancer and enlarged prostate glands (benign prostatic hypertrophy). Before your doctor injects Nebido, he/she will examine you to check that you do not have prostate cancer.</p><p>Your doctor will regularly examine your prostate and breast, especially if you are elderly. He/she will also take regular blood samples.</p><p>Following the use of hormonal substances such as androgen compounds, cases of benign (non-cancerous) and malignant (cancerous) liver tumours have been observed to occur.</p><p>&nbsp;</p><p><strong>Other medicines and Nebido</strong></p><p><strong>Tell your doctor or pharmacist</strong> if you are using or have recently used or might <strong>use any other medicines</strong>, including medicines obtained without a prescription. The doctor may need to adjust the dose if you are using any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the hormone ACTH or corticosteroids (used to treat various conditions such as rheumatism, arthritis, allergic conditions and asthma): Nebido may increase the risk of water retention, especially if your heart and/or liver are not working properly</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood-thinning tablets (coumarin derived oral anticoagulants) since this can increase the risk of bleeding. Your doctor will check the dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines used to treat diabetes. It may be necessary to adjust the dose of your blood sugar reducing medicine. Like other androgens, testosterone may increase the effect of insulin.</p><p>&nbsp;</p><p><strong>Please be sure to inform your doctor if you suffer from a disturbance of blood clotting</strong>, because this is important for your doctor to know before deciding to inject Nebido.</p><p>&nbsp;</p><p>Nebido may also affect the results of some laboratory tests (e.g. thyroid gland). Tell your doctor or the laboratory staff that you are using Nebido.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Nebido is not for use in women and must not be used in pregnant or breast-feeding women.</p><p><strong>Fertility</strong></p><p>Treatment with high doses of testosterone preparations commonly may reversibly stop or reduce sperm production (see also under &ldquo;Possible side effects&rdquo;).</p><p><strong>Driving and using machines</strong></p><p>Nebido has no observed effect on your ability to drive or use machines.</p><p><strong>Nebido contains benzyl benzoate</strong></p><p>Nebido contains 2000 mg benzyl benzoate in each 4 ml vial which is equivalent to 500 mg/ml.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor will inject Nebido (1 vial) very slowly into a muscle. He/she will give you the injections every 10 to 14 weeks. This is enough to maintain sufficient testosterone levels without leading to a build-up of testosterone in the blood.</p><p>&nbsp;</p><p>Nebido is strictly for intramuscular injection. Special care will be taken to avoid injection into a blood vessel (see<strong> &ldquo;</strong><em>Administration</em>&rdquo;).</p><p>&nbsp;</p><p><strong>Start of treatment</strong></p><p>Your doctor will measure your blood testosterone levels before starting treatment and during the early stages of treatment. Your doctor may give you the second injection after only six weeks in order to quickly reach the necessary testosterone level. This will depend on your symptoms and testosterone levels.</p><p>&nbsp;</p><p><strong>Maintaining your testosterone levels during treatment</strong></p><p>The injection interval should always be within the recommended range of 10 to 14 weeks.</p><p>Your doctor will measure your testosterone levels regularly at the end of an injection interval to make sure it is at the right level. If the level is too low, your doctor may decide to give you injections more often. If your testosterone levels are high, your doctor may decide to give you injections less often. Do not miss your injection appointments. Otherwise, your optimum level of testosterone will not be maintained.</p><p>&nbsp;</p><p>If you think that the effect of Nebido is too strong or too weak, talk to your doctor.</p><p>&nbsp;</p><p><strong>If you use more Nebido than you should</strong></p><p>Symptoms of having too much Nebido include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritability</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nervousness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight gain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; long-lasting or frequent erections</p><p>&nbsp;</p><p>Tell your doctor, if you have any of these. Your doctor will inject it less often or will stop treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The <strong>most common side effects</strong> are acne and pain where the injection is given.</p><p>&nbsp;</p><p><strong>Common side effects</strong> (may affect up to 1 in 10 patients):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormally high levels of red blood cells</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight gain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hot flushes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acne</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; enlarged prostate and associated problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; various reactions where the injection was given (e.g. pain, bruising or irritation)</p><p>&nbsp;</p><p><strong>Uncommon side effects</strong> (may affect up to 1 in 100 patients):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased appetite, changes in blood test results (e.g. increased blood sugars or fats)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression, emotional disorder, insomnia, restlessness, aggression, or irritability</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache, migraine, or tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cardiovascular disorder, high blood pressure, or dizziness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bronchitis, sinusitis, cough, shortness of breath, snoring, or voice problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea, or nausea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes in liver test results</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hair loss, or various skin reactions (e.g. itching, reddening or dry skin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain, pain in limbs, muscle problems (e.g. spasm, pain or stiffness), or an increased creatine phosphokinase in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary tract disorders (e.g. decreased flow of urine, urinary retention, urge to pass urine at night)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prostatic disorders (e.g. prostatic dysplasia, or hardening or inflammation of the prostate), changes in sexual appetite, painful testicles, painful, hardened or enlarged breasts, or increased levels of male and female hormones</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness, general feeling of weakness, excessive sweating, or night sweats</p><p>&nbsp;</p><p><strong>Rare side effects</strong> (may affect up to 1 in 1000 patients):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The oily liquid Nebido may reach the lungs (pulmonary micro embolism of oily solutions) which can in rare cases lead to signs and symptoms such as cough, shortness of breath, feeling generally unwell, excessive sweating, chest pain, dizziness, &ldquo;pins and needles&rdquo;, or fainting. These reactions may occur during or immediately after the injection and are reversible.</p><p>&nbsp;</p><p>Suspected anaphylactic reactions after Nebido injection have been reported.</p><p>&nbsp;</p><p>In addition to the side effects listed above the following have been reported following treatment with preparations containing testosterone: nervousness, hostility, brief interruptions in breathing during sleep, various skin reactions including dandruff and oily skin, increased hair growth, more frequent erections, and very rare cases of yellowing of the skin and eyes (jaundice).</p><p>&nbsp;</p><p>Treatment with high doses of testosterone preparations commonly stops or reduces sperm production, although this returns to normal after treatment ceases. Testosterone replacement therapy of poorly functioning testicles (hypogonadism) can in rare cases cause persistent, painful erections (priapism). High‑dosed or long-term administration of testosterone occasionally increases the occurrences of water retention and oedema (swelling due to fluid retention).</p><p>&nbsp;</p><p>For testosterone products in general a common risk of increased red blood cell count, haematocrit (percentage of red blood cells in blood) and haemoglobin (the component of red blood cells that carries oxygen), were observed by periodic blood tests.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC)</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not store above 25&deg;C.</p><p>&nbsp;</p><p><strong>Do not</strong> use this medicine after the expiry date which is stated on the carton and the label after &quot;EXP&quot;. The expiry date refers to the last day of that month.</p><p><strong>Do not </strong>throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Nebido contains</strong></p><p><u>&nbsp;</u></p><p>The active substance is testosterone undecanoate 250&nbsp;mg/ml (corresponding to 157.9&nbsp;mg testosterone). One vial contains 1000&nbsp;mg testosterone undecanoate (corresponding to 631.5&nbsp;mg testosterone).</p><p>&nbsp;</p><p>The other ingredients are benzyl benzoate and refined castor oil.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Nebido looks like and contents of the pack
	
Nebido is a clear, colourless to yellowish-brown oily liquid. The contents of the packs are: 

1 brown glass vial with 4 ml solution for injection

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturer</strong></p><p>Bayer AG</p><p>M&uuml;llerstrasse 178</p><p>13353 Berlin, Germany.</p><p><strong>&nbsp;</strong></p><p><strong>Marketing Authorisation Holder</strong></p><p>Bayer AG,</p><p>Kaiser-Wilhelm-Allee 1</p><p>51368 Leverkusen, Germany.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in October 2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي نبيدو على الهرمون الذكري تستوستيرون كمادة فعالة. يحقن نبيدو فى العضل. يتم تخزينه في العضل و يتم اطلاقه تدريجياً على مدى فترة طويلة من الزمن.</p><p dir="RTL">يستخدم نبيدو فى علاج الذكور البالغين للمعالجة بالاستعاضة باستخدام التستوستيرون لعلاج مشاكل مختلفة سببها نقص التستوستيرون (قصور الغدد التناسلية للذكر). يجب تأكيد هذه العلامات السريرية باثنين من القياسات المستقلة لتركيزات هرمون التستوستيرون في الدم بصورة متبادلة.</p><p dir="RTL">قد تشمل العلامات السريرية على ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العجز الجنسي (العنة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العقم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الرغبة الجنسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وهن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مزاج مكتئب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان المادة العظمية بسبب انخفاض تركيزات الهرمون</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا تحتاج معرفته قبل أن تُعطى نبيدو</strong></p><p dir="RTL"><strong>لا تستخدم نبيدو:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية للتستوستيرون أنديكانوويت أو لأى من المكونات الاخرى لهذ الدواء (مذكورة في جزء 6)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك الان، أو في أي وقت مضى، سرطان للبروستات أو للغدة الثديية، إما مشتبه به او مؤكد، الذى يكون تنشيطه محفز بالهرمونات الجنسية الذكرية (أندروجينات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك الان، أو في أي وقت مضى، ورم فى الكبد</p><p dir="RTL"><strong>لا يستخدم</strong> نبيدو في السيدات.</p><p dir="RTL"><strong>التحذيرات و الاحتياطات</strong></p><p dir="RTL"><strong>أبلغ طبيبك</strong> إذا كان لديك الآن، أو في أي وقت مضى، أي من الأمراض الاتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صرع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض في القلب، الكلى أو الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع نصفى (شقيقة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انقطاع مؤقت للتنفس أثناء النوم (حدوث توقف قصير للتنفس أثناء النوم)، لأنها قد تصبح أسوأ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان، حيث أن تركيزات الكالسيوم في الدم قد تحتاج الى مراقبة منتظمة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم أو إذا كنت تعالج من ارتفاع ضغط الدم، فإن هرمون التستوستيرون قد يؤدي إلى ارتفاع في ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات في تجلط الدم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النزف (الهيموفيليا)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ثرومبوفيليا (اضطراب تجلط الدم والتي تزيد من خطر تكوين الجلطات في الأوعية الدموية)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العوامل التي تزيد من خطر الإصابة بالجلطات الدموية في الوريد: جلطات الدم السابقة في الوريد؛ التدخين؛ السمنة; السرطان؛ عدم الحركة؛ إذا كان أحد أفراد عائلتك المباشرة قد تعرض لجلطات دموية في الساق أو الرئة أو أي عضو آخر في سن مبكرة (على سبيل المثال، دون سن الخمسين). أو كلما كبرت في السن.</p><p dir="RTL">كيفية التعرف على تجلط الدم: تورم مؤلم في ساق واحدة أو تغيير مفاجئ في لون الجلد على سبيل المثال تحول شاحب, أحمر أو أزرق, ضيق التنفس المفاجئ, السعال المفاجئ غير المبرر الذي قد يجلب دم; أو ألم صدري مفاجئ ، الدوار الشديد، ألم شديد في معدتك، فقدان مفاجئ للرؤية. اطلب الرعاية الطبية العاجلة إذا واجهت أحد هذه الأعراض</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>اذا كنت تعاني من اضطراب شديد للقلب، الكبد أو الكلى</strong>،</p><p dir="RTL">العلاج بنبيدو يمكن أن يسبب مضاعفات خطيرة بسبب بداية تراكم السوائل في الجسم، الذي يمكن أن يصاحبه أحياناً تراكم للدم (قصور قلبي إحتقانى).</p><p dir="RTL">وينبغي إجراء الاختبارات الدم الآتية من قبل طبيبك قبل وأثناء العلاج:</p><p dir="RTL">مستوى هرمون التستوستيرون في الدم، و تعداد الدم الكامل.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>إذا كان الكبد لا يعمل بشكل طبيعي</strong></p><p dir="RTL">لم يتم القيام بدراسات تقليدية في مرضى لديهم خلل في وظيفة الكبد.إذا كان لديك في أي وقت مضى ورم في الكبد، لن يتم وصف نبيدو لك (أنظر &laquo; لا تستخدم نبيدو&raquo;).</p><p dir="RTL"><strong>الأطفال و المراهقين</strong><strong> </strong></p><p dir="RTL">يجب عدم استخدام نبيدو في الأطفال و المراهقين. غير متوفر بيانات لاستخدام نبيدو في المراهقين الذكور تحت سن 18 عاما.</p><p dir="RTL"><strong>المرضى كبار السن (65 سنة أو أكثر)</strong></p><p dir="RTL">إذا كنت أكثر من 65 عاماً، عموماً لن يجري طبيبك أي تعديل للجرعة (انظر &laquo;الفحوصات الطبية / المتابعة&raquo;).</p><p dir="RTL"><strong>بناء العضلات واختبارات تعاطي المنشطات</strong></p><p dir="RTL">نبيدو ليس مناسبا لزيادة بنا العضلات لدى الأشخاص الأصحاء أو لتقوية الأداء البدني.</p><p dir="RTL">يمكن أن يؤدي استخدام نبيدو إلى نتائج إيجابية في اختبارات تعاطي المنشطات.</p><p dir="RTL"><strong>إساءة استخدام الدواء و الاعتماد عليه</strong></p><p dir="RTL">تناول دائمًا هذا الدواء تمامًا كما قال لك الطبيب أو الصيدلي.</p><p dir="RTL">يمكن أن يسبب تعاطي هرمون التستوستيرون ، خاصة إذا كنت تتناول الكثير من هذا الدواء بمفرده أو مع المنشطات الأندروجينية الأخرى، مشاكل صحية خطيرة للقلب والأوعية الدموية (التي يمكن أن تؤدي إلى الوفاة)، الصحة العقلية و /أو الكبد.</p><p dir="RTL">قد يصبح الأفراد الذين أساءوا استخدام هرمون التستوستيرون معتمدين عليه وقد يعانون من أعراض الانسحاب عندما تتغير الجرعة بشكل ملحوظ أو يتم إيقافها على الفور. يجب عدم إساءة استخدام هذا الدواء بمفرده أو مع المنشطات الأندروجينية الأخرى لأنه يحمل مخاطر صحية خطيرة. (انظر &laquo;الآثار الجانبية المحتملة&raquo;.)</p><p dir="RTL"><strong>الفحوصات الطبية / المتابعة</strong></p><p dir="RTL">الهرمونات الذكرية الجنسية يمكن أن تسبب تسريع نمو سرطان البروستات (البروستات) الموجود من قبل أو تسبب تضخم حميد للبروستات (تضخم حميد للبروستات). قبل حقن نبيدو، سوف يقوم طبيبك بفحصك للتأكد من عدم وجود سرطان البروستات.</p><p dir="RTL">سوف يجرى لك الطبيب فحص منتظم للبروستات والثدي، بالأخص للمرضى كبار السن . سوف يقوم الطبيب أيضاً بأخذ عينات للدم بانتظام.</p><p dir="RTL">تم ملاحظة حدوث حالات أورام حميدة (غير سرطانية) و أورام خبيثة (سرطانية) للكبد عندما يتم استخدام مواد هرمونية مثل مستحضرات تحتوي على الأندروجين (منشطات الذكورة).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أدوية أخرى و نبيدو</strong></p><p dir="RTL"><strong>الرجاء إبلاغ طبيبك أو الصيدلي</strong> أذا كنت تستعمل أو قد استعملت حديثاً أي مستحضرات دوائية أخرى، تشمل الأدوية التي تحصل عليها بدون وصفة طبية. قد يحتاج طبيبك لضبط الجرعة إذا كنت تتناول أو تستخدم واحد أو العديد من الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هرمون الـ ACTH (الهرمون الموجه لقشرة الكظر &ndash; هرمون محدد للغدة النخامية) أو الستيرويد القشري (يستخدم لعلاج حالات مختلفة مثل الروماتيزم، التهاب المفاصل، حالات الحساسية و الربو): يمكن لنبيدو أن يزيد من مخاطر تراكم السوائل في الأنسجة، خاصة إذا كنت تعاني من مرض في القلب أو الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاقراص التي تمنع الدم من التجلط (مضادات التجلط الفموية المشتقة من الكومارين) لأن هذا يمكن أن يزيد من خطر النزيف. طبيبك سوف يتحقق من الجرعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة في علاج مرض السكري. قد يكون من الضروري تعديل الجرعة من الدواء المستخدم لتقليل نسبة السكر في الدم. مثل الاندروجينات الأخرى، التستوستيرون قد يزيد من تأثير الانسولين.</p><p dir="RTL"><strong>يرجى التأكد من إبلاغ الطبيب إذا كنت تعاني من اضطراب في تجلط الدم</strong>، لأن من المهم أن يعلم طبيبك ذلك قبل أن يقرر الحقن بنبيدو.</p><p dir="RTL">يمكن ايضاً أن يؤثر نبيدو على نتائج بعض الاختبارات المعملية (مثل الغدة الدرقية). اخطر طبيبك أنك تستعمل نبيدو.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل و الرضاعة الطبيعية</strong></p><p dir="RTL">نبيدو غير مخصص للاستخدام لدى السيدات و لا يجب استخدام نبيدو لدى السيدات الحوامل أو السيدات اللاتي ترضعن طبيعي.</p><p dir="RTL"><strong>الخصوبة</strong></p><p dir="RTL">العلاج بجرعات عالية من التستوستيرون عادة قد يؤدي إلى نتيجة عكسية بوقف أو تقليل إنتاج الحيوانات المنوية (انظر أيضا &laquo;الآثار الجانبية المحتملة&raquo;)</p><p dir="RTL"><strong>القيادة و استخدام الماكينات</strong></p><p dir="RTL">نبيدو لا يؤثر على مهارات القيادة أو تشغيل الماكينات.</p><p dir="RTL"><strong>يحتوي نبيدو على بنزيل بنزوات</strong></p><p dir="RTL">يحتوي نبيدو على 2000 مجم بنزيل بنزوات في كل عبوة زجاجية (فيال)&nbsp; سعة 4 مل والتي تعادل 500 مجم / مل</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سوف يقوم الطبيب بحقن نبيدو (عبوة زجاجية واحدة) ببطء شديد داخل العضلة.</p><p dir="RTL">سوف تعطى الحقن كل 10 الى 14 أسبوع. سوف يكون ذلك كافي ليبقي مستويات التستوستيرون كافية بدون أن يسبب أي تراكم للتستوستيرون في الدم.</p><p dir="RTL">نبيدو يستخدم فقط للحقن داخل العضل. يجب أن تؤخذ عناية خاصة لتجنب الحقن داخل وعاء دموي (انظر &laquo;إعطاء الدواء&raquo;).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>بداية العلاج</strong></p><p dir="RTL">سوف يقوم الطبيب بقياس تركيزات التستوستيرون في الدم قبل بداية العلاج و خلال المراحل المبكرة من العلاج.</p><p dir="RTL">قد يعطيك طبيبك الحقنة الثانية بعد 6 أسابيع فقط للوصول بسرعة إلى مستوى هرمون التستوستيرون اللازم. و هذا سوف يعتمد على الأعراض التي لديك و على مستويات هرمون التستوستيرون في دمك.</p><p dir="RTL"><strong>الاحتفاظ بمستويات التستوستيرون أثناء العلاج</strong></p><p dir="RTL">الفترة الفاصلة بين الحقن يجب أن تظل ضمن المدى الموصي به وهو من 10 إلى 14 أسبوع.</p><p dir="RTL">سوف يقوم طبيبك بقياس تركيزات التستوستيرون في الدم عند نهاية كل فترة فاصلة بين الحقن ليتأكد من أنها عند المستوى الصحيح.</p><p dir="RTL">اذا كان المستوى منخفض جداً، قد يعطيك طبيبك الحقن بتكرار أكثر. اذا كانت مستويات التستوستيرون عالية، قد يعطيك طبيبك الحقن بتكرار أقل. لا تفوت ميعاد الحقن. وإلاّ، لن يتم الاحتفاظ بالمستويات الأمثل من التستوستيرون في دمك.</p><p dir="RTL">الرجاء إبلاغ طبيبك إذا كان لديك الانطباع أن تأثير نبيدو شديد جداً أو ضعيف جداً.</p><p dir="RTL"><strong>إذا استخدمت نبيدو أكثر مما يجب</strong></p><p dir="RTL">أعراض استخدام نبيدو أكثر مما يجب تشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عصبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انتصاب مطول أو متكرر</p><p dir="RTL">الرجاء إبلاغ طبيبك، إذا كان لديك أي من هذه الاعراض. طبيبك سوف يحقن نبيدو بتكرار أقل أو سوف يوقف العلاج.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كل الادوية، قد يسبب نبيدو آثار جانبية، مع انه ليس من الضرورى أن يصاب بها كل شخص.</p><p dir="RTL">الآثار الجانبية الاكثر شيوعا هى حب الشباب وألم فى مكان الحقن.</p><p dir="RTL"><strong>الاثار الجانبية الشائعة (يمكن أن تصيب 1 من كل 10 مرضى):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع غير طبيعي لخلايا الدم الحمراء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبات ساخنة (توهّج الوجه)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حب الشباب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم البروستاتا والمشاكل المرتبطة بها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعلات مختلفة في مكان الحقن (مثل الم، رضه أو تهيج)</p><p dir="RTL"><strong>الاثار الجانبية الغير شائعة (يمكن أن تصيب 1 من كل 100 مريض):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاعل حساسية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في الشهية، تغيرات فى نتائج اختبار الدم (مثل زيادة سكر الدم أو الدهون)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اكتئاب، اضطراب المزاج، أرق، توتر، عدوانية أو هياج</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع، شقيقة (صداع نصفى)،أو رعشة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلل للجهاز القلبي الوعائي، ارتفاع فى ضغط الدم، أو دوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الشعب الهوائية، التهاب الجيوب الانفية، سعال،&nbsp; قصور في التنفس، شخير أو مشاكل في الصوت</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال، أو غثيان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في نتائج اختبار الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشعر أو تفاعلات جلدية متنوعة (مثل هرشٍ، احمرار أو جفاف الجلد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في المفاصل، ألم بالأطراف، مشاكل في العضلات (مثل تشنج،&nbsp; ألم أو تصلب)، أو زيادة انزيم كرياتين الفوسفوكينيز في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات المسالك البولية (مثل نقص في جريان البول، احتباس البول، الضرورة الى التبول في الليل)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات للبروستات (مثل خلل تنسج البروستاتا، تصلب و التهاب البروستات)، تغير في الرغبة الجنسية، ألم الخصية، ألم، تصلب أو تضخم الثدي، زيادة الهرمونات الذكرية أو الانثوية في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعب (وهن)، شعور عام بالضعف، زيادة العرق، أو عرق ليلي</p><p dir="RTL"><strong>الاثار الجانبية النادرة (يمكن أن تصيب 1 من كل 1000 مريض):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السائل الزيتى لنبيدو قد يصل الى الرئة (انسداد وعاء دموي رئوى مجهري (متناهى الصغر) بسبب المحاليل الزيتية) التي تؤدى في حالات نادرة الى مظاهر و أعراض مثل السعال، ضيق فى التنفس، احساس عام بالتوعك، زيادة العرق،&nbsp; ألم في الصدر، دوخة، &laquo;إحساس بوخز و تنميل&raquo; و إِغْماء. هذه التفاعلات قد تحدث إما خلال أو مباشرة بعد الحقن وهى تكون قابلة للانعكاس (غير دائمة).</p><p dir="RTL">تم التبليغ عن اشباه حدوث تفاعلات شديدة و فورية للحساسية بعد حقن نبيدو.</p><p dir="RTL">بالإضافة الى الآثار الجانبية المدونة أعلاه، الآثار الجانبية الاتية قد تم الابلاغ عنها أثناء العلاج بمستحضرات تحتوى على تستوستيرون: عصبية، عداء، انقطاع مؤقت للتنفس أثناء النوم (حدوث توقف قصير للتنفس أثناء النوم)، تفاعلات جلدية متنوعة تشمل قِشْرَةُ الرَّأْس وتزيت الجلد، زيادة نمو الشعر، تكرار الانتصاب و، نادراً جداً، اصفرار الجلد والعيون (يرقان).</p><p dir="RTL">العلاج بجرعات عالية من مستحضرات التستوستيرون يسبب عامة توقف أو نقص انتاج السائل المنوي (المنى)، هذه التغيرات تعود لطبيعتها بعد التوقف عن العلاج. إن المعالجة بالاستعاضة للتستوستيرون في حالة انخفاض وظيفة الخصية (قصور الغُدَدِ التَّناسُلِيَّة) ، في حالات نادرة يمكن أن يسبب انتصابات مؤلمة متواصلة (القساح: بقاء الإنعاظ).</p><p dir="RTL">أحيانا تناول جرعات عالية أو لفترات زمنية طويلة لمستحضرات التستوستيرون تؤدي الى زيادة حدوث تراكم السوائل و وذمات (ورم بسبب تراكم السوائل).</p><p dir="RTL">بشكل عام، بالنسبة للمنتجات التستوستيرون فقد لوحظ خطر في زيادة عدد خلايا الدم الحمراء، الهيماتوكريت (النسبة المئوية للخلايا الدم الحمراء في الدم) والهيموجلوبين (المكون من خلايا الدم الحمراء التي تحمل الأكسجين)، من خلال اختبارات الدم الدورية</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">اذا تم إصابتك بأي آثار جانبية، تحدث إلى طبيبك أو الصيدلي. هذا يشمل أي آثار جانبية محتملة غير مذكورة في هذه النشرة. يمكن أن يساعد التبليغ عن الآثار الجانبية على توفير مزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية:</strong></p><p dir="RTL"><strong>السعودية:</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز اتصال الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: https://ade.sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ هذا الدواء بعيداً عن متناول نظر و أيدي الأطفال.</p><p dir="RTL">يحفظ عند درجة حرارة لا تزيد عن 25 درجة مئوية .</p><p dir="RTL">لا تستخدم نبيدو بعد تاريخ انتهاء المفعول المذكور على الكرتونة والملصق بعد &laquo;EXP&raquo;. تاريخ انتهاء المفعول يشير الى آخر يوم في هذا الشهر.</p><p dir="RTL">لا يجب التخلص من أي أدوية عن طريق الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الادوية التي لم تعد في حاجة إليها. هذه الاجراءات سوف تساعد على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي نبيدو</strong></p><p dir="RTL">المادة الفعالة هي: تستوستيرون أنديكانوويت 250 ميليغرام/ميليلتر (يعادل 157.9 ميليغرام تستوستيرون).</p><p dir="RTL">تحتوي كل فيال (عبوة زجاجية) على 1000 ميليغرام تستوستيرون أنديكانوويت (يعادل 631.5 ميليغرام تستوستيرون)</p><p dir="RTL">المكونات الأخرى هي: بنزوات البنزيل و زيت الخروع المكرر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو شكل نبيدو و محتويات العبوة</strong></p><p dir="RTL">نبيدو سائل زيتي صافي، &nbsp;عديم اللون إلى اللون البني المصفر.</p><p dir="RTL">محتويات العبوة: 1 عبوة زجاجية (فيال) بنية اللون بها 4 ميليلتر محلول للحقن</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>المصنع:</strong></p><p dir="RTL">باير ايه جى</p><p dir="RTL">مولر شتراس 178</p><p dir="RTL">13353 برلين، ألمانيا.</p><p dir="RTL"><strong>حامل تصريح التسويق</strong></p><p dir="RTL">باير ايه جي</p><p dir="RTL">قيصر-ويلهلم - آلي 1</p><p dir="RTL">51368 ليفركوزن، ألمانيا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت آخر مراجعة لنشرة العبوة هذه في أكتوبر 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Nebido 1000 mg/4 ml, solution for injection.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ml solution for injection contains 250 mg testosterone undecanoate corresponding to 157.9 mg testosterone.

Each vial with 4 ml solution for injection contains 1000 mg testosterone undecanoate corresponding to 631.5 mg testosterone.
Excipient with known effect: 
2000 mg benzyl benzoate per vial.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.

Clear, colourless to yellowish-brown oily solution.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p><em>&nbsp;</em></p><p>One vial of<strong><em> </em></strong>Nebido (corresponding to 1000 mg testosterone undecanoate) is injected every 10 to 14 weeks. Injections with this frequency are capable of maintaining sufficient testosterone levels and do not lead to accumulation.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>Start of treatment</u></p><p><em>&nbsp;</em></p><p>Serum testosterone levels should be measured before start and during initiation of treatment. Depending on serum testosterone levels and clinical symptoms, the first injection interval may be reduced to a minimum of 6 weeks as compared to the recommended range of 10 to 14 weeks for maintenance. With this loading dose, sufficient steady state testosterone levels may be achieved more rapidly.</p><p>&nbsp;</p><p><u>Maintenance and individualisation of treatment</u></p><p>The injection interval should be within the recommended range of 10 to 14 weeks. Careful monitoring of serum testosterone levels is required during maintenance of treatment. It is advisable to measure testosterone serum levels regularly. Measurements should be performed at the end of an injection interval and clinical symptoms considered. These serum levels should be within the lower third of the normal range. Serum levels below normal range would indicate the need for a shorter injection interval. In case of high serum levels an extension of the injection interval may be considered.</p><p><s>&nbsp;</s></p><p><strong>Special populations</strong></p><p><s>&nbsp;</s></p><p><u>Paediatric population</u></p><p><em>&nbsp;</em></p><p>Nebido is not indicated for use in children and adolescents and it has not been clinically evaluated in males under 18 years of age (see section 4.4).</p><p>&nbsp;</p><p><u>Geriatric patients</u></p><p><em>&nbsp;</em></p><p>Limited data do not suggest the need for a dosage adjustment in elderly patients (see section 4.4).</p><p>&nbsp;</p><p><u>Patients with hepatic impairment</u></p><p><em>&nbsp;</em></p><p>No formal studies have been performed in patients with hepatic impairment. The use of Nebido is contraindicated in men with past or present liver tumours (see section 4.3).</p><p>&nbsp;</p><p><u>Patients with renal impairment</u></p><p><em>&nbsp;</em></p><p>No formal studies have been performed in patients with renal impairment.</p><p>&nbsp;</p><p><strong>Method of administration</strong></p><p>For intramuscular use.</p><p>&nbsp;</p><p>The injections must be administered very slowly (over two minutes). Nebido is strictly for intramuscular injection. Care should be taken to inject Nebido deeply into the gluteal muscle following the usual precautions for intramuscular administration. Special care must be taken to avoid intravasal injection (see section 4.4 under &ldquo;Application&rdquo;). The contents of a vial are to be injected intramuscularly immediately after opening.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The use of Nebido is contraindicated in men with:
•	androgen-dependent carcinoma of the prostate or of the male mammary gland
•	past or present liver tumours
•	hypersensitivity to the active substance or to any of the excipients (listed in section 6.1).

The use of Nebido in women is contraindicated.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nebido is not recommended for use in children and adolescents.</p><p>&nbsp;</p><p>Nebido should be used only if hypogonadism (hyper- and hypogonadotrophic) has been demonstrated and if other aetiology, responsible for the symptoms, has been excluded before treatment is started. Testosterone insufficiency should be clearly demonstrated by clinical features (regression of secondary sexual characteristics, change in body composition, asthenia, reduced libido, erectile dysfunction etc.) and confirmed by two separate blood testosterone measurements.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>Elderly population</u></p><p><u>&nbsp;</u></p><p>There is limited experience on the safety and efficacy of the use of Nebido in patients over 65 years of age.<strong><em> </em></strong>Currently, there is no consensus about age specific testosterone reference values. However, it should be taken into account that physiologically testosterone serum levels are lower with increasing age.</p><p>&nbsp;</p><p><u>Medical examination and laboratory tests</u></p><p><em>&nbsp;</em></p><p><em>Medical examinations</em></p><p>Prior to testosterone initiation, all patients must undergo a detailed examination in order to exclude a risk of pre-existing prostatic cancer. Careful and regular monitoring of the prostate gland and breast must be performed in accordance with recommended methods (digital rectal examination and estimation of serum PSA) in patients receiving testosterone therapy at least once yearly and twice yearly in elderly patients and at risk patients (those with clinical or familial factors). Local guidelines for safety monitoring under testosterone replacement therapy should be taken into consideration.</p><p><em>&nbsp;</em></p><p><em>Laboratory tests</em></p><p>Testosterone level should be monitored at baseline and at regular intervals during treatment. Clinicians should adjust the dosage individually to ensure maintenance of eugonadal testosterone levels. In patients receiving long-term androgen therapy, the following laboratory parameters should also be monitored regularly: haemoglobin and haematocrit, liver function tests and lipid profile (see section 4.8).</p><p>&nbsp;</p><p>Due to variability in laboratory values, all measures of testosterone should be carried out in the same laboratory.</p><p>&nbsp;</p><p><u>Tumours </u></p><p><em>&nbsp;</em></p><p>Androgens may accelerate the progression of sub-clinical prostatic cancer and benign prostatic hyperplasia.</p><p>&nbsp;</p><p>Nebido should be used with caution in cancer patients at risk of hypercalcaemia (and associated hypercalciuria), due to bone metastases. Regular monitoring of serum calcium concentrations is recommended in these patients.</p><p>&nbsp;</p><p>Cases of benign and malignant liver tumours have been reported in users of hormonal</p><p>substances such as androgen compounds. If severe upper abdominal complaints, liver enlargement or signs of intra-abdominal haemorrhage occur in men using Nebido, a liver tumour should be included in the differential-diagnostic considerations.</p><p>&nbsp;</p><p><u>Cardiac, hepatic or renal insufficiency</u></p><p><em>&nbsp;</em></p><p>In patients suffering from severe cardiac, hepatic or renal insufficiency or ischaemic heart disease, treatment with testosterone may cause severe complications characterised by oedema with or without congestive cardiac failure. In such case, treatment must be stopped immediately.</p><p>&nbsp;</p><p><em>Hepatic or renal insufficiency</em></p><p>There are no studies undertaken to demonstrate the efficacy and safety of this medicinal<strong><em> </em></strong>product in patients with renal or hepatic impairment. Therefore, testosterone replacement therapy should be used with caution in these patients.</p><p>&nbsp;</p><p><em>Cardiac insufficiency</em></p><p>Caution should be exercised in patients predisposed to oedema, e.g. in case of severe cardiac, hepatic, or renal insufficiency or ischaemic heart disease, as treatment with androgens may result in increased retention of sodium and water. In case of severe complications characterized by oedema with or without congestive heart failure treatment must be stopped immediately (see section 4.8).</p><p>Testosterone may cause a rise in blood pressure and Nebido should be used with caution in men with hypertension.&nbsp;</p><p><em>&nbsp;</em></p><p><em>Clotting disorders</em></p><p>As a general rule, the limitations of using intramuscular injections in patients with acquired or inherited bleeding disorders always have to be observed.</p><p>Testosterone and derivatives have been reported to increase the activity of coumarin derived oral anticoagulants (see also section 4.5).</p><p>Testosterone should be used with caution in patients with thrombophilia or risk factors for venous thromboembolism (VTE), as there have been post-marketing studies and reports of thrombotic events (e.g. deep-vein thrombosis, pulmonary embolism, ocular thrombosis) in these patients during testosterone therapy. In thrombophilic patients, VTE cases have been reported even under anticoagulation treatment, therefore continuing testosterone treatment after first thrombotic event should be carefully evaluated. In case of treatment continuation, further measures should be taken to minimise the individual VTE risk.</p><p>&nbsp;</p><p><u>Other conditions</u></p><p>&nbsp;</p><p>Nebido should be used with caution in patients with epilepsy and migraine, as the conditions may be aggravated.</p><p>&nbsp;</p><p>Improved insulin sensitivity may occur in patients treated with androgens who achieve normal testosterone plasma concentrations following replacement therapy. Therefore, the dosage of hypoglycaemic agents may need to be lowered.</p><p>&nbsp;</p><p>Certain clinical signs: irritability, nervousness, weight gain, prolonged or frequent erections may indicate excessive androgen exposure requiring dosage adjustment.</p><p>&nbsp;</p><p>Pre-existing sleep apnoea may be potentiated.</p><p>&nbsp;</p><p>Athletes treated for testosterone replacement in primary and secondary male hypogonadism should be advised that the medicinal product contains an active substance which may produce a positive reaction in anti-doping tests.</p><p>&nbsp;</p><p>Androgens are not suitable for enhancing muscular development in healthy individuals or for increasing physical ability.</p><p><s>&nbsp;</s></p><p>Nebido should be permanently withdrawn if symptoms of excessive androgen exposure persist or reappear during treatment with the recommended dosage regimen.</p><p>&nbsp;</p><p><u>Drug abuse and dependence</u></p><p><u>&nbsp;</u></p><p>Testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication(s) and in combination with other anabolic androgenic steroids.</p><p>Abuse of testosterone and other anabolic androgenic steroids can lead to serious adverse reactions including: cardiovascular (with fatal outcomes in some cases), hepatic and/or psychiatric events. Testosterone abuse may result in dependence and withdrawal symptoms upon significant dose reduction or abrupt discontinuation of use. The abuse of testosterone and other anabolic androgenic steroids carries serious health risks and is to be discouraged.</p><p>&nbsp;</p><p><u>Application</u></p><p><em>&nbsp;</em></p><p>As with all oily solutions, Nebido must be injected strictly intramuscularly and very slowly (over two minutes). Pulmonary microembolism of oily solutions can in rare cases lead to signs and symptoms such as cough, dyspnoea, malaise, hyperhidrosis, chest pain, dizziness, paraesthesia, or syncope. These reactions may occur during or immediately after the injection and are reversible. The patient should therefore be observed during and immediately after each injection in order to allow for early recognition of possible signs and symptoms of pulmonary oily microembolism. Treatment is usually supportive, e.g. by administration of supplemental oxygen.</p><p>&nbsp;</p><p>Suspected anaphylactic reactions after Nebido injection have been reported.</p><p>&nbsp;</p><p><u>Information about excipients</u></p><p>This medicine contains 2000 mg Benzyl benzoate in each 4 ml vial which is equivalent to 500 mg/ml.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Oral anti-coagulants</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>Testosterone and derivatives have been reported to increase the activity of coumarin derived oral anti-coagulants.<s> </s>Patients receiving oral anti-coagulants require close monitoring, especially at the beginning or end of androgen therapy. Increased monitoring of the prothrombin time, and INR determinations, are recommended.</p><p>&nbsp;</p><p><u>Other interactions</u></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>The concurrent administration of testosterone with ACTH or corticosteroids may enhance oedema formation; thus these active substances<strong><em> </em></strong>should be administered cautiously, particularly in patients with cardiac or hepatic disease or in patients predisposed to oedema.</p><p>&nbsp;</p><p>Laboratory test interactions: Androgens may decrease levels of thyroxin-binding globulin resulting in decreased total T4 serum levels and increased resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged, however, and there is no clinical evidence of thyroid dysfunction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Fertility</u></p><p>&nbsp;</p><p>Testosterone replacement therapy may reversibly reduce spermatogenesis (see sections 4.8 and 5.3).&nbsp;&nbsp;</p><p>&nbsp;</p><p><u>Pregnancy and breastfeeding</u></p><p>&nbsp;</p><p>Nebido is not indicated for use in women and must not be used in pregnant or breast-feeding women (see section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nebido has no influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>Regarding undesirable effects associated with the use of androgens, please also refer to section 4.4.</p><p>&nbsp;</p><p>The most frequently reported undesirable effects during treatment with Nebido are acne and injection site pain.</p><p>Pulmonary microembolism of oily solutions can in rare cases lead to signs and symptoms such as cough, dyspnoea, malaise, hyperhidrosis, chest pain, dizziness, paraesthesia, or syncope. These reactions may occur during or immediately after the injection and are reversible. Cases suspected by the company or the reporter to represent oily pulmonary microembolism have been reported rarely in clinical trials (in &ge; 1/10,000 and &lt; 1/1,000 injections) as well as from postmarketing experience (see section 4.4).</p><p><s>&nbsp;</s></p><p>Suspected anaphylactic reactions after Nebido injection have been reported.</p><p><s>&nbsp;</s></p><p>Androgens may accelerate the progression of sub-clinical prostatic cancer and benign prostatic hyperplasia.</p><p>&nbsp;</p><p>Table 1 below reports adverse drug reactions (ADRs) by MedDRA system organ classes (MedDRA SOCs) reported with Nebido. The frequencies are based on clinical trial data and defined as common (&ge;&nbsp;1/100 to &lt; 1/10), uncommon (&ge; 1/1000 to &lt;1/100) and rare (&ge; 1/10,000 to &lt; 1/1,000). The ADRs were recorded in 6 clinical studies (N=422) and considered at least possibly causally related to Nebido.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p><em>Table 1: </em><em>Categorised relative frequency of men with ADRs, by MedDRA SOC &ndash; based on pooled data of six</em><em>, clinical trials, N=422 (100.0%), i.e.N=302 hypogonadal men treated with i.m. injections of 4 ml and N=120 with 3ml of TU 250 mg/ml</em></p><table border="1" cellspacing="0" cellpadding="0" style="width:652px"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common<br />(</strong><strong>&sup3;</strong><strong>&nbsp;1/100 to &lt;&nbsp;1/10)</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon<br />(</strong><strong>&sup3;</strong><strong> 1/1000 to &lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p><p><strong>(</strong><strong>&sup3;</strong><strong> 1/10,000 to &lt; 1/1,000)</strong></p><p><strong>&nbsp;</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>Polycythaemia</p><p>Haematocrit increased*</p><p>Red blood cell count increased*</p><p>Haemoglobin increased*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>Weight increased</p></td><td style="vertical-align:top"><p>Increased appetite</p><p>Glycosylated haemoglobin increased<br />Hypercholesterolaemia</p><p>Blood triglycerides increased</p><p>Blood cholesterol increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depression</p><p>Emotional disorder</p><p>Insomnia</p><p>Restlessness</p><p>Aggression</p><p>Irritability</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Headache</p><p>Migraine</p><p>Tremor</p><p>&nbsp;</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>Hot flush</p></td><td style="vertical-align:top"><p>Cardiovascular disorder</p><p>Hypertension</p><p>Dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bronchitis<br />Sinusitis<br />Cough</p><p>Dyspnoea</p><p>Snoring</p><p>Dysphonia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diarrhoea</p><p>Nausea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Liver function test abnormal</p><p>Aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders </strong></p></td><td style="vertical-align:top"><p>Acne</p></td><td style="vertical-align:top"><p>Alopecia</p><p>Erythema</p><p>Rash<sup>1</sup></p><p>Pruritus</p><p>Dry skin</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia</p><p>Pain in extremity</p><p>Muscle disorder<sup>2</sup></p><p>Musculoskeletal stiffness</p><p>Blood creatine phosphokinase increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders </strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Urine flow decreased</p><p>Urinary retention</p><p>Urinary tract disorder</p><p>Nocturia</p><p>Dysuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive system and breast disorders </strong></p></td><td style="vertical-align:top"><p>Prostatic specific antigen increased</p><p>Prostate examination abnormal</p><p>Benign prostatic hyperplasia</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Prostatic dysplasia</p><p>Prostate induration</p><p>Prostatitis</p><p>Prostatic disorder</p><p>Libido disorder</p><p>Testicular pain</p><p>Breast induration</p><p>Breast pain</p><p>Gynaecomastia</p><p>Oestradiol increased</p><p>Blood testosterone increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>Various kinds of injection site reactions<sup>3</sup></p></td><td style="vertical-align:top"><p>Fatigue</p><p>Asthenia</p><p>Hyperhidrosis<sup>4</sup></p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning</strong></p><p><strong>and procedural</strong></p><p><strong>complications</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary oil</p><p>microembolism**</p></td></tr></tbody></table><p>*Respective frequency has been observed in relation to the use in testosterone containing products.<br />** Frequency is based on the number of injections.</p><p>The most appropriate MedDRA term to describe a certain adverse reaction is listed. Synonyms or related conditions are not listed, but should be taken into account as well.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Rash including Rash papular</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Muscle disorder: Muscle spasms, Muscle strain and Myalgia</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Various kinds of injection site reaction: Injection site pain, Injection site discomfort, Injection site pruritus, Injection site erythema, Injection site haematoma, Injection site irritation, Injection site reaction</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <sup>4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Hyperhidrosis: Hyperhidrosis and Night sweats</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p>Pulmonary microembolism of oily solutions can in rare cases lead to signs and symptoms such as cough, dyspnoea, malaise, hyperhidrosis, chest pain, dizziness, paraesthesia, or syncope. These reactions may occur during or immediately after the injections and are reversible. Cases suspected by the company or the reporter to represent oily pulmonary microembolism have been reported rarely in clinical trials (in &ge; 1/10,000 and &lt; 1/1,000 injections) as well as from postmarketing experience (see section 4.4).</p><p>&nbsp;</p><p>In addition to the above mentioned adverse reactions, nervousness, hostility, sleep apnoea, various skin reactions including seborrhoea, increased hair growth, increased frequency of erections and in very rare cases jaundice have been reported under treatment with testosterone containing preparations.</p><p>&nbsp;</p><p>Therapy with high doses of testosterone preparations commonly reversibly interrupts or reduces spermatogenesis, thereby reducing the size of the testicles; testosterone replacement therapy of hypogonadism can in rare cases cause persistent, painful erections (priapism). High-dosed or long-term administration of testosterone occasionally increases the occurrences of water retention and oedema.</p><p><u>&nbsp;</u></p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>SFDA call center: 19999.</p><p>E - mail: npc.drug@sfda.gov.sa.</p><p>Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special therapeutic measure apart from termination of therapy with the medicinal product<em> </em>or dose reduction is necessary after overdose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Androgens, 3-oxoandrosten (4) derivatives</p><p>ATC code: G03B A03</p><p>&nbsp;</p><p>Testosterone undecanoate is an ester of the naturally occurring androgen, testosterone. The active form, testosterone, is formed by cleavage of the side chain.</p><p>&nbsp;</p><p>Testosterone is the most important androgen of the male, mainly synthesised in the testicles, and to a small extent in the adrenal cortex.</p><p>&nbsp;</p><p>Testosterone is responsible for the expression of masculine characteristics during foetal, early childhood, and pubertal development and thereafter for maintaining the masculine phenotype and androgen-dependent functions (e.g. spermatogenesis, accessory sexual glands). It also performs functions, e.g.&nbsp; in the skin, muscles, skeleton, kidney, liver, bone marrow, and CNS.</p><p>&nbsp;</p><p>Dependent on the target organ, the spectrum of activities of testosterone is mainly androgenic (e.g. prostate, seminal vesicles, epididymis) or protein-anabolic (muscle, bone, haematopoiesis, kidney, liver).</p><p>&nbsp;</p><p>The effects of testosterone in some organs arise after peripheral conversion of testosterone to estradiol, which then binds to estrogen receptors in the target cell nucleus e.g. the pituitary, fat, brain, bone, and testicular Leydig cells.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>&nbsp;</p><p>Nebido is an intramuscularly administered depot preparation of testosterone undecanoate and thus circumvents the first-pass effect. Following intramuscular injection of testosterone undecanoate as an oily solution, the compound is gradually released from the depot and is almost completely cleaved by serum esterases into testosterone and undecanoic acid. An increase in<strong><em> </em></strong>serum levels of testosterone above basal values may be seen one day after administration.</p><p>&nbsp;</p><p><u>Steady-state conditions</u></p><p>&nbsp;</p><p>After the 1<sup>st</sup> intramuscular injection of 1000 mg testosterone undecanoate to hypogonadal men, mean Cmax values of 38 nmol/L (11 ng/mL) were obtained after 7 days. The second dose was administered 6 weeks after the 1<sup>st</sup> injection and maximum testosterone concentrations of about 50 nmol/L (15 ng/mL) were reached. A constant dosing interval of 10 weeks was maintained during the following 3 administrations and steady-state conditions were achieved between the 3<sup>rd</sup> and the 5<sup>th</sup> administration. Mean Cmax and Cmin values of testosterone at steady-state were about 37 (11 ng/mL) and 16 nmol/L (5 ng/mL), respectively. The median intra- and inter-individual variability (coefficient of variation, %) of Cmin values was 22 % (range: 9-28%) and 34% (range: 25-48%), respectively.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>In serum of men, about 98% of the circulating testosterone is bound to sex hormone binding globulin<strong><em> </em></strong>(SHBG) and albumin. Only the free fraction of testosterone is considered as biologically active. Following intravenous infusion of testosterone to elderly men, the elimination half-life of testosterone was approximately one hour and an apparent volume of distribution of about 1.0 l/kg was determined.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Testosterone which is generated by ester cleavage from testosterone undecanoate is metabolised and excreted the same way as endogenous testosterone. The undecanoic acid is metabolised by &szlig;-oxidation in the same way as other aliphatic carboxylic acids.<strong><em> </em></strong>The major active metabolites of testosterone are oestradiol and dihydrotestosterone.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Testosterone undergoes extensive hepatic and extrahepatic metabolism.&nbsp; After the administration of radio-labelled testosterone, about 90% of the radioactivity appears in the urine as glucuronic and sulphuric acid conjugates and 6% appears in the faeces after undergoing enterohepatic circulation. Urinary medicinal products include androsterone and etiocholanolone. Following intramuscular administration of this depot formulation the release rate<strong><em> </em></strong>is characterised by a half life of 90&plusmn;40 days.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Toxicological studies have not revealed other effects than those which can be explained based on the hormone profile of Nebido.</p><p>&nbsp;</p><p>Testosterone has been found to be non-mutagenic in vitro using the reverse mutation model (Ames test) or hamster ovary cells. A relationship between androgen treatment and certain cancers has been found in studies on laboratory animals. Experimental data in rats have shown increased incidences of prostate cancer after treatment with testosterone.</p><p>&nbsp;</p><p>Sex hormones are known to facilitate the development of certain tumours induced by known carcinogenic agents. The clinical relevance of the latter observation is not known.</p><p>&nbsp;</p><p>Fertility studies in rodents and primates have shown that treatment with testosterone can impair fertility by suppressing spermatogenesis in a dose dependent manner.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Benzyl benzoate</p><p>Castor oil, refined</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years

The medicinal product must be used immediately after first opening.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Vial</u></p><p><u>&nbsp;</u></p><p>6ml brown glass (type I) vial with grey bromobutyl (foil-clad ETFE) injection stopper and bordered cap, containing a fill volume of 4 ml.</p><p>Pack size: 1 x 4 ml</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>At cold storage temperatures the properties of this oil-based solution might temporarily change (e.g. higher viscosity, cloudiness). If stored at cold temperature, the product should be brought to room or body temperature before use.</p><p>&nbsp;</p><p>The solution for intramuscular injection is to be visually inspected prior to use and only clear solutions free from particles should be used.</p><p>&nbsp;</p><p>The medicinal product is for single use only and any unused solution should be discarded in accordance with local requirements.</p><p>&nbsp;</p><p><u>Vial</u></p><p>The vial is for single use only. The content of a vial is to be injected intramuscularly immediately after drawing up into the syringe. After removal of the plastic cap (A) do not remove the metal ring (B) or the crimp cap (C).</p><p><img alt="" src="data:image/png;base64,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" /></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bayer AG,
Leverkusen, Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10 November 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>